Diligence memo · auto-generated · as of July 2, 2026
Emmaus Life Sciences, Inc.
Emmaus Life Sciences, Inc. looks under-valued against its niche peers and is at-risk on financing cadence.
Businessfiled
Emmaus Life Sciences, Inc. operates in Pharmaceuticals, based in TORRANCE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Emmaus Life Sciences, Inc. has raised $103M in disclosed capital across 25 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $34M on 2023-01-12.
Most recent recorded round closed around 2023-01-30.
Valuation (modeled)modeled
Provath models Emmaus Life Sciences, Inc. at approximately $2.9M (range $494K–$6.8M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.02× the median modeled value of Series B Pharmaceuticals companies in 2022–2024 (51 peers) — value vs value, same stage and era. Issuer reports $5M–$25M revenue while modeled below niche peers.
Financing rhythm & timingmixed
Historic cadence: a new round about every 5 months.
Last raise 3.4 yr ago; this sector typically re-raises about every 13 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
The last round was 144.7× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 91% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 5% of those peers.
Closest niche peers: MedAvail Holdings, Inc., Revalesio Corp, Kinaset Therapeutics, Inc., Venatorx Pharmaceuticals, Inc., Cxl Ophthalmics, Inc..
Peoplefiled
24 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.